IMEX   05356
INSTITUTO DE MEDICINA EXPERIMENTAL
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Severe thrombocytopenia as a predictor of survival and response to hypomethylating agents: data from a Latin-American cohort
Autor/es:
IASTREBNER, MARCELO; BASQUIERA, ANA L; KORNBLIHTT, LAURA; PINTOS, NOEMÍ; ROSENHAIN, MARIANA; BELLI, CAROLINA; GONZALEZ, JACQUELINE; CRISP, RENÉE; MACCHIAVELLO, E; BENGIÓ, RAQUEL; GUSMAO, BRENO; LAZZARINO, CAROLINA; ARBELBIDE, JORGE; ESPINOSA, DANIEL; PERESSIN, R; RIVAS, M MARTA; PRATES, M VIRGINIA
Lugar:
Estocolmo
Reunión:
Congreso; 23rd Congress of the European Hematology Association; 2018
Institución organizadora:
European Hematology Association
Resumen:
Background: Hypomethylating agents (HMA) are the first line option for high-risk patient and lower-risk patient with transfusiondependence, or, during the follow-up according to worsening clinical features. Thrombocytopenia is a frequent finding inmyelodysplastic syndromes (MDS) during the course of the disease and, recently, severe thrombocytopenia (